JPH0597789A - Alpha-hydroxyglycinamide derivative and its production - Google Patents

Alpha-hydroxyglycinamide derivative and its production

Info

Publication number
JPH0597789A
JPH0597789A JP3256536A JP25653691A JPH0597789A JP H0597789 A JPH0597789 A JP H0597789A JP 3256536 A JP3256536 A JP 3256536A JP 25653691 A JP25653691 A JP 25653691A JP H0597789 A JPH0597789 A JP H0597789A
Authority
JP
Japan
Prior art keywords
group
mmol
derivative
solvent
protecting group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP3256536A
Other languages
Japanese (ja)
Inventor
Kenji Hayakawa
謙二 早川
Genji Iwasaki
源司 岩崎
Shinichiro Matsunaga
伸一郎 松永
Toshio Kokubo
利雄 小久保
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NIPPON CHIBAGAIGII KK
Ciba Geigy Japan Ltd
Original Assignee
NIPPON CHIBAGAIGII KK
Ciba Geigy Japan Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NIPPON CHIBAGAIGII KK, Ciba Geigy Japan Ltd filed Critical NIPPON CHIBAGAIGII KK
Priority to JP3256536A priority Critical patent/JPH0597789A/en
Publication of JPH0597789A publication Critical patent/JPH0597789A/en
Pending legal-status Critical Current

Links

Classifications

    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

PURPOSE:To obtain the subject compound useful for producing C-end amidated peptides by treating an-alpha-hydroxyglycine derivative with ammonia in a solvent and optionally eliminating the amino-protecting group. CONSTITUTION:A compound of formula I (R<1> is H, lower alkyl, benzyl, etc.; R<2> is H or amino-protecting group; R<3> is H or carboxyl protecting group) is dissolved in a solvent such as ethanol, treated with introduced ammonia preferably at 0-25 deg.C and then optionally the protecting group is eliminated to give the objective derivative of formula II and its salt. For example, alpha-t- butyldimethylsilyloxy-N-t-butoxycarbonylglycinamide may be cited as the derivative.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【産業上の利用分野】本発明はα−ヒドロキシグリシン
誘導体及びその塩に関し、この化合物はC−末端アミド
化ペプチドの製造のために有用である。
FIELD OF THE INVENTION The present invention relates to α-hydroxyglycine derivatives and salts thereof, which compounds are useful for the preparation of C-terminal amidated peptides.

【0002】[0002]

【従来の技術】生理活性のためにC−末端がアミド化さ
れていることを必須とする種々のペプチド性生理活性物
質が知られている。これらの生理活性ペプチドの例とし
てメラニン細胞刺激ホルモン放出抑制ホルモン(Pro-Le
u-Gly-NH2)〔R.M.G.Nairら、Biochem.Biophys.Res.Comm
un., 43 , 1376(1971);M.E.Celis ら、Pro.Nat.Acad.S
ci., USA, 68, 1428(1971)、甲状腺刺激ホルモン放出ホ
ルモン(Pyro・Glu-His-Pro-NH2)〔K.Folkers ら、Bioc
hem.Biophys.Res.Commum., 37 , 123, 705(1969);Endo
crinol., 86 , 1143(1970);R.Burgusら、Compt.Rend.A
cad.Sci., 269 ,1870(1969);Nature, 226 , 321(197
0)、等が挙げられる。
2. Description of the Related Art Various peptide-based physiologically active substances which are essential to have an amidated C-terminal for physiological activity are known. Examples of these bioactive peptides include melanocyte-stimulating hormone release inhibitory hormone (Pro-Le
u-Gly-NH 2 ) (RMGNair et al., Biochem.Biophys.Res.Comm
un., 43 , 1376 (1971); MECelis et al., Pro.Nat.Acad.S.
ci., USA, 68 , 1428 (1971), thyrotropin-releasing hormone (PyroGlu-His-Pro-NH 2 ) [K. Folkers et al., Bioc.
hem.Biophys.Res.Commum., 37 , 123, 705 (1969); Endo
crinol., 86 , 1143 (1970); R. Burgus et al., Compt. Rend.A.
cad.Sci., 269 , 1870 (1969); Nature, 226 , 321 (197)
0), etc.

【0003】これらの生理活性C−末端アミド化ペプチ
ドの製造方法としては、ペプチドのC−末端のカルボキ
シル基をアンモニアによりアミド化する方法〔Zhang Ho
ngliang ら、Yiyao Gongye 3 , 3(1983);Chem.Abst.9
9, 639(1983) ;Vlassa M., Rev.Roum.Chim., 21 , 455
(1976) ;Rivaille Pierreら、Helv.Chim.Acta 54 ,355
(1971) ;Folkers Karlら、J.Med.Chem. 14, 475-6(197
1) ;Beyerman, H.Cら、Rect.Trav.Chim.Pays-Bus, 90
, 791(1971) ;Folkers Karlら、Chem.Abst., 79, 459
(1973) 〕、グリシンアミド又はプロリンアミドとの化
学的又は酵素的縮合反応による方法〔Muro Tetsuo ら、
Agric.Biol.Chem., 51, 1207(1987);Flouret George,
J.Med.Chem., 13 , 843(1970) ;Flouret George, Che
m.Abst., 75, 246(1971) ;Wissmann Hans ら、Chem.Ab
st., 76, 449(1972) ;H.Chitoshiら、Biochem.Biophy
s.Res.Commun., 60 , 1345(1974);Kurath P. ら、Hel
v. Chim.Acta., 56, 1656(1973);Bienert Michael
ら、Chem.Abst.86, 455(1976) ;Bienert M., Pharmazi
e 32, 397(1977) 〕が知られている。
As a method for producing these physiologically active C-terminal amidated peptides, a method of amidating the C-terminal carboxyl group of the peptide with ammonia [Zhang Ho
ngliang et al., Yiyao Gongye 3 , 3 (1983); Chem. Abst. 9
9 , 639 (1983) ; Vlassa M., Rev. Roum. Chim., 21 , 455
(1976) ; Rivaille Pierre et al., Helv. Chim. Acta 54 , 355.
(1971); Folkers Karl et al., J. Med. Chem. 14 , 475-6 (197.
1) ; Beyerman, HC et al., Rect.Trav.Chim.Pays-Bus, 90.
, 791 (1971); Folkers Karl et al., Chem. Abst., 79 , 459.
(1973)], a method by a chemical or enzymatic condensation reaction with glycinamide or prolinamide [Muro Tetsuo et al.
Agric.Biol.Chem., 51 , 1207 (1987); Flouret George,
J.Med.Chem., 13 , 843 (1970) ; Flouret George, Che
m.Abst., 75 , 246 (1971); Wissmann Hans et al., Chem. Ab.
st., 76 , 449 (1972); H. Chitoshi et al., Biochem. Biophy.
s.Res.Commun., 60 , 1345 (1974); Kurath P. et al., Hel
v. Chim. Acta., 56 , 1656 (1973) ; Bienert Michael
Chem. Abst. 86 , 455 (1976); Bienert M., Pharmazi.
e 32 , 397 (1977)] is known.

【0004】しかしながら、前記の化学的方法において
は、保護されたC−末端カルボキシル基とアンモニアガ
スとを反応せしめる方法であり、この場合光学活性ペプ
チドのラセミ化を促進するため、ラセミ化を伴わずにC
−末端をアミド化することはできない。
However, the above-mentioned chemical method is a method of reacting a protected C-terminal carboxyl group with ammonia gas. In this case, since racemization of the optically active peptide is promoted, racemization is not involved. To C
-The end cannot be amidated.

【0005】[0005]

【発明が解決しようとする課題】従って本発明はラセミ
化を伴わないでペプチドのC−末端アミド化を行うため
の新規な手段を提供しようとするものである。
The present invention therefore seeks to provide a novel means for carrying out the C-terminal amidation of peptides without racemization.

【0006】[0006]

【課題を解決するための手段】本発明者らは、上記の課
題を解決すべく種々検討した結果、次の式(I):
As a result of various studies to solve the above problems, the inventors of the present invention obtained the following formula (I):

【化3】 で示される化合物をアミノ基供与体として使用すること
により、C−末端カルボキシル基が保護されていないペ
プチドの該カルボキシル基を、ラセミ化を伴わないでア
ミド化できることを見出し、本発明を完成した。
[Chemical 3] The present invention was completed by finding that the carboxyl group of a peptide whose C-terminal carboxyl group is not protected can be amidated without racemization by using the compound represented by the formula (3) as an amino group donor.

【0007】従って本発明は、次の式(I):Accordingly, the present invention provides the following formula (I):

【化4】 (式中、R1 は水素原子、低級アルキル基、低級アルケ
ニル基、低級アルキニル基、ベンジル基又はアルキル基
によりもしくはアルキル基と芳香族基とにより置換され
たシリル基を表わし;R2 は水素原子又はアミノ保護基
を表わす)により表わされるα−ヒドロキシグリシンア
ミド誘導体、及びその塩を提供する。
[Chemical 4] (In the formula, R 1 represents a hydrogen atom, a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a benzyl group or a silyl group substituted by an alkyl group or an alkyl group and an aromatic group; R 2 represents a hydrogen atom. Or an amino-protecting group), and an α-hydroxyglycinamide derivative thereof, and a salt thereof.

【0008】本発明はさらに、前記のα−ヒドロキシグ
リシンアミド誘導体又はその塩の製造方法であって、次
の式(II):
The present invention further provides a method for producing the aforementioned α-hydroxyglycinamide derivative or a salt thereof, which comprises the following formula (II):

【化5】 〔式中、R1 及びR2 は式(I)において定義したのと
同じ意味を有し、そしてR3 は水素原子又はカルボキシ
ル保護基である〕で表わされるα−ヒドロキシグリシン
誘導体を溶媒中アンモニアで処理し、所望によりアミノ
保護基を除去し、そして所望により得られた化合物をそ
の塩に転換することを特徴とする方法を提供する。
[Chemical 5] [Wherein R 1 and R 2 have the same meaning as defined in formula (I), and R 3 is a hydrogen atom or a carboxyl-protecting group]. And optionally removing the amino protecting group and optionally converting the resulting compound into its salt.

【0009】本発明はさらに、アミノ酸もしくはペプチ
ドを又はこれらの誘導体を前記のα−ヒドロキシグリシ
ン誘導体と反応せしめることを特徴とするC−末端アミ
ド化ペプチドの製造方法を提供する。
The present invention further provides a method for producing a C-terminal amidated peptide, which comprises reacting an amino acid or peptide or a derivative thereof with the aforementioned α-hydroxyglycine derivative.

【0010】[0010]

【具体的な説明】本発明において、R1 の低級アルキル
基は6個以下、好ましくは4個以下の炭素原子を有する
アルキル基であり、例えばメチル基、エチル基、n−プ
ロピル基、イソプロピル基、n−ブチル基、イソブチル
基、tert−ブチル基、分岐していてもよいペンチル
基又は分岐していてもよいヘキシル基である。
DETAILED DESCRIPTION OF THE INVENTION In the present invention, the lower alkyl group for R 1 is an alkyl group having 6 or less, preferably 4 or less carbon atoms, such as methyl group, ethyl group, n-propyl group and isopropyl group. , N-butyl group, isobutyl group, tert-butyl group, optionally branched pentyl group, or optionally branched hexyl group.

【0011】R1 の低級アルケニル基は、炭素原子数6
個以下、そして好ましくは4個以下のアルケニル基であ
り、例えばエテニル基、アリル基、任意の位置に二重結
合を有するブテニル基等である。R1 の低級アルキニル
基は、炭素原子数6個以下、そして好ましくは4個以下
のアルキニル基、例えばエチニル基、等である。
The lower alkenyl group for R 1 has 6 carbon atoms.
The number of alkenyl groups is not more than 4, and preferably not more than 4, and examples thereof include an ethenyl group, an allyl group, and a butenyl group having a double bond at any position. The lower alkynyl group for R 1 is an alkynyl group having 6 or less, and preferably 4 or less carbon atoms, such as an ethynyl group.

【0012】R1 の低級アルキル基により置換されたシ
リル基は、1〜3個の低級アルキル基により置換された
シリル基であり、この場合の低級アルキル置換基は、R
1 について前に記載した低級アルキル基のいずれか、又
はそれらの組合せである。低級アルキル基により置換さ
れたシリル基は、好ましくはtert−ブチルジメチル
シリル基である。アルキル及び芳香族基により置換され
たシリル基は、前記のアルキル基及びフェニル基により
置換されたシリル基であり、例えばtert−ブチルジ
フェニルシリル基である。
The silyl group substituted by the lower alkyl group of R 1 is a silyl group substituted by 1 to 3 lower alkyl groups, and the lower alkyl substituent in this case is R 1.
It is any of the lower alkyl groups previously described for 1 or a combination thereof. The silyl group substituted by a lower alkyl group is preferably a tert-butyldimethylsilyl group. The silyl group substituted with an alkyl or aromatic group is a silyl group substituted with the above alkyl group and a phenyl group, and is, for example, a tert-butyldiphenylsilyl group.

【0013】R2 のアミノ保護基としては、アミノ酸又
はペプチド化学の分野において常用されている保護基を
使用することができ、例えばオキシカルボニル型保護
基、例えばベンジルオキシカルボニル(Cbz−)、p
−メトキシベンジルオキシカルボニル〔Z(OMe)
−〕、tert−ブトキシカルボニル(Boc−)、又
は2−ビフェニルイソプロポキシカルボニル(Bpoc
−)等;アシル型保護基、例えばHCO−、フタレート
基(Pht−)、又はo−ニトロフェニルチオ基(Np
s−)等;あるいはアルキル基保護基、例えばトリフェ
ニルメチル基(Trt−)等を用いることができる。
As the amino protecting group for R 2, a protecting group commonly used in the field of amino acid or peptide chemistry can be used, for example, an oxycarbonyl type protecting group such as benzyloxycarbonyl (Cbz-), p.
-Methoxybenzyloxycarbonyl [Z (OMe)
-], Tert-butoxycarbonyl (Boc-), or 2-biphenylisopropoxycarbonyl (Bpoc)
-) Etc .; acyl-type protecting groups such as HCO-, phthalate groups (Pht-), or o-nitrophenylthio groups (Np).
s-) and the like; or an alkyl group-protecting group such as a triphenylmethyl group (Trt-) and the like can be used.

【0014】本発明のα−ヒドロキシグリシンアミド誘
導体の塩は酸付加塩であり、例えば無機塩、例えばハロ
ゲン化水素酸塩、例えば弗化水素酸塩、塩酸塩もくしは
臭化水素酸塩、硝酸塩、硫酸塩、又はリン酸塩、あるい
は有機酸塩、例えば蟻酸塩、酢酸塩、等が挙げられる。
The salt of the α-hydroxyglycinamide derivative of the present invention is an acid addition salt, for example, an inorganic salt such as a hydrohalide salt such as hydrofluoride salt, hydrochloride or hydrobromide salt, Examples thereof include nitrates, sulfates or phosphates, or organic acid salts such as formates and acetates.

【0015】本発明の式(I)により示される化合物
は、例えば、次の式(II)
The compound represented by the formula (I) of the present invention can be obtained, for example, by the following formula (II)

【化6】 〔式中、R1 及びR2 は式(I)において定義したのと
同じ意味を有し、そしてR3 は水素又はカルボニル保護
基である〕で表わされるα−ヒドロキシグリシン誘導体
を溶媒中でアンモニアで処理し、所望によりアミノ保護
基R2 を除去することにより製造することができる。
[Chemical 6] [Wherein R 1 and R 2 have the same meaning as defined in formula (I), and R 3 is hydrogen or a carbonyl protecting group], and the α-hydroxyglycine derivative is ammonia in a solvent. Can be prepared by treating with and removing the amino protecting group R 2 if desired.

【0016】カルボニル保護基R3 はアンモニアによる
処理によりアミノ基により置換され得る常用のカルボキ
シ保護基であり、例えば、低級アルキルオキシ基、例え
ばメトキシ基(−OMe)、エトキシ基(−OEt)、
ベンジルオキシ基(−OBzl)又はtert−ブトキ
シ基(−OtBu)、あるいはアリールオキシ基、例え
ばp−ニトロフェノキシ基(−ONp)、等である。
The carbonyl protecting group R 3 is a customary carboxy protecting group which can be replaced by an amino group by treatment with ammonia, for example a lower alkyloxy group such as a methoxy group (-OMe), an ethoxy group (-OEt),
A benzyloxy group (-OBzl) or a tert-butoxy group (-OtBu), or an aryloxy group such as a p-nitrophenoxy group (-ONp).

【0017】反応のための溶媒としては、低級アルコー
ル、例えばメタノール、エタノール、プロパノール、エ
ーテル、例えばメチルエチルエーテル、ジエチルエーテ
ル、イソプロピルエーテル、等、常用の有機溶媒を使用
することができる。反応は式(II)で示される化合物を
前記の溶媒に溶解した溶液にアンモニアを、例えば−7
8℃〜40℃、好ましくは0℃〜25℃、例えば室温に
おいて、減圧下、常圧下又は加圧下で、吹き込むことに
より行うことができる。
As a solvent for the reaction, a conventional organic solvent such as a lower alcohol such as methanol, ethanol, propanol, an ether such as methyl ethyl ether, diethyl ether, isopropyl ether and the like can be used. The reaction is carried out by adding ammonia to a solution prepared by dissolving the compound represented by the formula (II) in the above solvent, for example, -7
It can be carried out by blowing at 8 ° C. to 40 ° C., preferably 0 ° C. to 25 ° C., for example, room temperature under reduced pressure, normal pressure or increased pressure.

【0018】この反応により、R2 がアミノ保護基であ
る本発明の化合物(I)が得られる。この化合物からR
2 のアミノ保護基を除去してR2 が水素である本発明の
化合物(I)を得るには、アミノ保護基R2 の種類に応
じて通常の脱保護処理を行えばよい。例えば保護基R2
がベンジルオキシカルボニル、P−メトキシベンジルオ
キシカルボニル等である場合、水素化触媒、例えばパラ
ジウム/炭素等の存在下で水素ガスで処理することによ
り脱保護を行うことができる。また保護基R2 がter
t−ブトキシカルボニルである場合、塩酸/ジオキサン
により脱保護を行うことができる。本発明の化合物
(I)の塩は、例えば前記脱保護処理を、酸、例えば塩
酸の存在下で行なうことにより製造することができる。
This reaction gives the compound (I) of the present invention in which R 2 is an amino-protecting group. R from this compound
In order to obtain the compound (I) of the present invention in which R 2 is hydrogen by removing the amino protecting group of 2 , usual deprotection treatment may be carried out depending on the kind of the amino protecting group R 2 . For example, the protecting group R 2
Is benzyloxycarbonyl, P-methoxybenzyloxycarbonyl or the like, deprotection can be carried out by treating with hydrogen gas in the presence of a hydrogenation catalyst such as palladium / carbon. In addition, the protecting group R 2 is ter
In the case of t-butoxycarbonyl, deprotection can be performed with hydrochloric acid / dioxane. The salt of the compound (I) of the present invention can be produced, for example, by carrying out the deprotection treatment in the presence of an acid such as hydrochloric acid.

【0019】中間体化合物(II)の内R1 が水素原子で
ない化合物は、例えば次の2つの方法により製造するこ
とができる。1つは式(II)で示される化合物の内R1
が水素である化合物に水素以外のR1 を導入することに
より製造することができる。水素以外の基R1 の導入
は、対応する基の官能性誘導体、例えばハロゲン誘導体
により行うことができる。例えば低級アルキル置換シリ
ル基の導入のためにはシリル基のハロゲン化物により、
例えばtert−ブトキシジメチルシリル基の導入には
塩化tert−ブチルジメチルシリルを用いることがで
きる。この反応はジメチルホルムアミド等の溶媒中0℃
〜30℃の温度において行うことができる。
A compound of the intermediate compound (II) in which R 1 is not a hydrogen atom can be produced, for example, by the following two methods. One is R 1 of the compounds represented by the formula (II)
It can be produced by introducing R 1 other than hydrogen into a compound in which is hydrogen. The introduction of groups R 1 other than hydrogen can be carried out by functional derivatives of the corresponding groups, for example halogen derivatives. For example, in order to introduce a lower alkyl-substituted silyl group, a halide of the silyl group,
For example, tert-butyldimethylsilyl chloride can be used to introduce a tert-butoxydimethylsilyl group. This reaction is performed in a solvent such as dimethylformamide at 0 ° C.
It can be carried out at a temperature of -30 ° C.

【0020】また、低級アルケニル又は低級アルキニル
基の導入のためには対応するアルケン又はアルキンのハ
ロゲン誘導体を用いることができ、例えばアリル基の導
入のためには、酸化銀のごとき触媒の存在下ヨウ化アリ
ルのごときハロゲン化アリルを用いて行うことができ
る。この反応は、例えばジメチルホルムアミド等の溶媒
中、−10℃〜50℃、好ましくは0℃〜25℃におい
て行うことができる。
Further, a halogen derivative of a corresponding alkene or alkyne can be used for introducing the lower alkenyl or lower alkynyl group. For example, for introducing the allyl group, iodide in the presence of a catalyst such as silver oxide can be used. It can be carried out using an allyl halide such as allyl halide. This reaction can be carried out in a solvent such as dimethylformamide at -10 ° C to 50 ° C, preferably 0 ° C to 25 ° C.

【0021】R1 が水素でない中間体化合物(II)を製
造するための他の方法は、R1 及びR3 が共に水素原子
である式(II)の化合物を、低級アルコール、例えばメ
タノール又はエタノールを溶媒として用いて塩化チオニ
ルにより処理する方法であり、この場合にはR1 及びR
3 が同一であり且つ前記低級アルコール溶媒に対応する
低級アルキル基である式(II)の化合物が得られる。こ
の反応は−10℃〜40℃、好ましくは0℃〜25℃に
おいて行うことができる。
Another method for preparing an intermediate compound (II) in which R 1 is not hydrogen is a compound of formula (II) in which R 1 and R 3 are both hydrogen atoms, and a lower alcohol such as methanol or ethanol. Is used as a solvent and treated with thionyl chloride. In this case, R 1 and R
A compound of formula (II) in which 3 is the same and is a lower alkyl group corresponding to the lower alcohol solvent is obtained. This reaction can be carried out at -10 ° C to 40 ° C, preferably 0 ° C to 25 ° C.

【0022】R1 が水素である式(II)の中間体は、例
えば次の2つの方法により製造することができる。一方
の方法によれば、グリセルアルデヒドCHO−COOH
をアミノ保護基R2 により保護されたアミンR2 NH2
と反応せしめることにより得られる。この反応は、例え
ばアセトン、エーテル等の溶媒中で20℃〜75℃に
て、例えばPhilip X.Masciantonio ら、米国特許No.
3,668,121;Stanlen D.Young ら、J.Am.Chem.
Soc.111 , 1933(1989)により記載されている方法により
行うことができる。この場合、R1 及びR3 が共に水素
原子である式(II)の化合物が得られる。
The intermediate of the formula (II) in which R 1 is hydrogen can be produced, for example, by the following two methods. According to one method, glyceraldehyde CHO-COOH
Amine protected with an amino protecting group R 2 R 2 NH 2
It is obtained by reacting with. This reaction is carried out, for example, in a solvent such as acetone or ether at 20 ° C to 75 ° C, for example, by Philip X. Masciantonio et al.
3,668,121; Stanlen D. Young et al., J. Am. Chem.
It can be performed by the method described by Soc. 111 , 1933 (1989). In this case, a compound of formula (II) in which both R 1 and R 3 are hydrogen atoms is obtained.

【0023】R1 が水素である式(II)の中間体を製造
するための他の方法は、次の式(III ):
Another method for preparing intermediates of formula (II) in which R 1 is hydrogen is the following formula (III):

【化7】 〔式中、R3 は式(II)において定義したのと同じ意味
を有し、そしてR4 は低級アルキル基を表わす〕により
示される化合物を、アミノ保護基R2 により保護された
アミンR2 NH2 と反応せしめる方法である。この反応
は、例えばテトラヒドロフラン等の溶媒中で20℃〜8
0℃の温度、例えば使用した溶媒の還流温度において行
うことができる。なお、前記R4 の低級アルキル基はR
1 の低級アルキル基と同じ意味を有する。
[Chemical 7] [Wherein R 3 has the same meaning as defined in formula (II), and R 4 represents a lower alkyl group], a compound R 2 protected by an amino protecting group R 2 This is a method of reacting with NH 2 . This reaction is carried out in a solvent such as tetrahydrofuran at 20 ° C to 8 ° C.
It can be carried out at a temperature of 0 ° C., for example at the reflux temperature of the solvent used. The lower alkyl group of R 4 is R
It has the same meaning as the lower alkyl group of 1 .

【0024】こうした得られた、式(I)で示される本
発明のヒドロキシグリシン誘導体を用いてペプチド又は
アミノ酸誘導体のC−末端のアミド化を行うことができ
る。このためには、式(I)の化合物と、C−末端が保
護されていないペプチドとを、非プロトン性溶媒、例え
ばジメチルホルムアミド(DMF)、ヘキサンメチルリ
ン酸トリアミド(HMPA)、ジメチルスルホキシド
(DMSO)等の中で、脱水縮合剤、例えばジシクロヘ
キシルカルボジイミド(DCC)、水溶性カルボジイミ
ド(WSCD)の存在下で反応させる。反応は、好まし
くは−50℃〜室温の範囲内で行う。
The C-terminal amidation of a peptide or amino acid derivative can be carried out by using the thus obtained hydroxyglycine derivative of the present invention represented by the formula (I). To this end, a compound of formula (I) and a peptide whose C-terminal is not protected are treated with an aprotic solvent such as dimethylformamide (DMF), hexanemethylphosphoric triamide (HMPA), dimethylsulfoxide (DMSO). ) And the like in the presence of a dehydration condensing agent such as dicyclohexylcarbodiimide (DCC) and water-soluble carbodiimide (WSCD). The reaction is preferably carried out within the range of -50 ° C to room temperature.

【0025】この方法は、例えば、C−末端がアミド化
された生理活性ペプチド、例えばメラニン細胞刺激ホル
モン放出抑制ホルモン、甲状腺刺激ホルモン放出ホルモ
ン、カルシトニン類、例えばヒトカルシトニン、サケカ
ルシトニン等の製造のために使用することができる。
This method is for producing, for example, a C-terminal amidated bioactive peptide such as a melanocyte-stimulating hormone release inhibitory hormone, thyroid stimulating hormone releasing hormone, calcitonins such as human calcitonin, salmon calcitonin and the like. Can be used for

【0026】次に、実施例により本発明をさらに具体的
に説明する。実施例1. 1−1 α−ヒドロキシ−N−tert−ブトキシカルボニルグ
リシンメチルエステル(4.11g,20mmol) とイミ
ダゾールを室温でDMFにとかし0℃に冷却した。更に
その溶液にその温度で塩化tert−ブチルジメチルシ
リルを加え、10分間攪拌した。溶液を室温に戻して1
時間攪拌した後、飽和食塩水を加え酢酸エチルにより抽
出した。有機層を無水硫酸マグネシウムで乾燥し、溶媒
を留去した。
Next, the present invention will be described more specifically with reference to examples. Example 1. 1-1 α-hydroxy-N-tert-butoxycarbonylglycine methyl ester (4.11 g, 20 mmol) and imidazole were dissolved in DMF at room temperature and cooled to 0 ° C. Further, tert-butyldimethylsilyl chloride was added to the solution at that temperature, and the mixture was stirred for 10 minutes. Bring the solution to room temperature 1
After stirring for an hour, saturated brine was added and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and the solvent was distilled off.

【0027】得られた油状物質をエタノール(50ml)
に溶かしその溶液に0℃で過剰のアンモニアを吹き込ん
だ後、余剰のアンモニアを減圧下で取り除き、さらにエ
タノールを留去して得た粗生成物をシリカゲルカラムク
ロマトグラフィーにより精製して、目的とするα−te
rt−ブチルジメチルシリルオキシ−N−tert−ブ
トキシカルボニルグリシンアミド(6.10g,qua
nt.)を得た。1HNHR δ(CDCl3) 0.16(s,3H), 0.21
(s,3H), 0.92(s,9H), 5.46(d,1H,J=9Hz), 5.63(d,1H,J=
9Hz), 6.22-6.82(br,2H)
The oily substance obtained was treated with ethanol (50 ml).
And blowing excess ammonia at 0 ° C. into the solution, the excess ammonia was removed under reduced pressure, and ethanol was distilled off to obtain a crude product, which was purified by silica gel column chromatography to obtain the desired product. α-te
rt-Butyldimethylsilyloxy-N-tert-butoxycarbonylglycinamide (6.10 g, qua
nt. ) Got. 1 HNHR δ (CDCl 3 ) 0.16 (s, 3H), 0.21
(s, 3H), 0.92 (s, 9H), 5.46 (d, 1H, J = 9Hz), 5.63 (d, 1H, J =
9Hz), 6.22-6.82 (br, 2H)

【0028】1−2 前記1−1の出発物質であるα−ヒドロキシ−N−te
rt−ブトキシカルボニルグリシンメチルエステルは次
の様にして製造した。カルバミン酸tert−ブチル
(2.83g,23.6mmol)とグリオキシル酸一水和
物(2.02g,21.5mmol)をアセトン(50ml)
に溶かし、一昼夜還流した。次にその溶液を0℃に冷却
し、その温度で過剰のジアゾメタン−エーテル溶液と処
理し、溶媒を留去した。
1-2 α-hydroxy-N-te which is the starting material of 1-1 above
rt-Butoxycarbonylglycine methyl ester was produced as follows. Tert-Butyl carbamate (2.83 g, 23.6 mmol) and glyoxylic acid monohydrate (2.02 g, 21.5 mmol) in acetone (50 ml)
And was refluxed for a whole day and night. The solution was then cooled to 0 ° C., treated with excess diazomethane-ether solution at that temperature and the solvent was distilled off.

【0029】その後飽和食塩水を加えクロロホルムによ
り抽出し、有機層を無水硫酸マグネシウムで乾燥、溶媒
を留去して得られた粗生成物をシリカゲルカラムクロマ
トグラフィーにより精製し、目的とするα−ヒドロキシ
−N−tert−ブトキシカルボニルグリシンメチルエ
ステル(2.56g,58%)を得た。1 HNMR δ(CDCl3) 1.46(s,9H),1.65(br s,1H), 3.84(s,3
H), 5.27-5.52(br,1H),5.59-5.90(br,1H) IR(NaCl) 1755(s), 1690(s), 1528(s)cm-1
Then, a saturated saline solution was added, the mixture was extracted with chloroform, the organic layer was dried over anhydrous magnesium sulfate, the solvent was distilled off, and the resulting crude product was purified by silica gel column chromatography to obtain the desired α-hydroxy group. -N-tert-Butoxycarbonylglycine methyl ester (2.56 g, 58%) was obtained. 1 HNMR δ (CDCl 3 ) 1.46 (s, 9H), 1.65 (br s, 1H), 3.84 (s, 3
H), 5.27-5.52 (br, 1H), 5.59-5.90 (br, 1H) IR (NaCl) 1755 (s), 1690 (s), 1528 (s) cm -1

【0030】1−3 前記1−1の出発物質であるα−ヒドロキシ−N−te
rt−ブトキシカルボニルグリシンメチルエステルを、
1−2とは別の方法によって製造した。カルバミン酸t
ert−ブチル(11.35g,95.0mmol)と1−
ヒドロキシ−1−メトキシ酢酸メチルエステル(14.
35g,119.5mmol)を無水THF(50ml)に溶
かして一昼夜還流した。その後いったん室温に戻して1
−ヒドロキシ−1−メトキシ酢酸メチルエステル(1.
15g,9.6mmol)を加え、更に8時間還流した。反
応溶液が室温に戻るまで放置した後、溶媒を留去し得ら
れた粗生成物をクロロホルム−ヘキサン溶液から再結晶
して、純粋なα−ヒドロキシ−N−tert−ブトキシ
カルボニルグリシンメチルエステル(16.42g,8
4%)を得た。
1-3 α-hydroxy-N-te which is the starting material of 1-1 above
rt-butoxycarbonylglycine methyl ester,
It was produced by a method different from 1-2 . Carbamic acid t
ert-butyl (11.35 g, 95.0 mmol) and 1-
Hydroxy-1-methoxyacetic acid methyl ester (14.
35 g, 119.5 mmol) was dissolved in anhydrous THF (50 ml) and refluxed for 24 hours. Then return to room temperature and
-Hydroxy-1-methoxyacetic acid methyl ester (1.
15 g, 9.6 mmol) was added and the mixture was refluxed for 8 hours. After leaving the reaction solution to return to room temperature, the solvent was distilled off and the obtained crude product was recrystallized from a chloroform-hexane solution to obtain pure α-hydroxy-N-tert-butoxycarbonylglycine methyl ester (16 .42g, 8
4%) was obtained.

【0031】実施例2.前記1−2又は1−3に従って
製造したα−ヒドロキシ−N−tert−ブトキシカル
ボニルグリシンメチルエステル(1.21g,5.9mm
ol)をDMF(10ml)に溶かし、室温で酸化銀(1.
04g,4.5mmol)及びヨウ化ベンジル(1.99
g,9.1mmol)を加えた。そのまま室温で一昼夜攪拌
した後、沈澱をろ別し母液に水を加えて酢酸エチルで抽
出した。抽出溶液を無水硫酸マグネシウムで乾燥した
後、溶媒を留去し、シリカゲルカラムクロマトグラフィ
ーにより粗精製した。
Example 2. Α-Hydroxy-N-tert-butoxycarbonylglycine methyl ester prepared according to 1-2 or 1-3 (1.21 g, 5.9 mm)
ol) was dissolved in DMF (10 ml) and silver oxide (1.
04 g, 4.5 mmol) and benzyl iodide (1.99)
g, 9.1 mmol) was added. The mixture was stirred at room temperature for 24 hours, the precipitate was filtered off, water was added to the mother liquor, and the mixture was extracted with ethyl acetate. The extract solution was dried over anhydrous magnesium sulfate, the solvent was evaporated, and the residue was roughly purified by silica gel column chromatography.

【0032】得られた油状物質をエタノール(50ml)
に溶かしその溶液に0℃で過剰のアンモニアを吹き込ん
だ後、余剰のアンモニアを減圧下で取り除き、溶媒を留
去して得られた粗生成物をシリカゲルカラムクロマトグ
ラフィーにより精製し、α−ベンジルオキシ−N−te
rt−ブトキシカルボニルグリシンアミド(0.397
g,22%)を得た。 m.p. 115−120 ℃1 HNMR δ(CDCl3) 1.44(s,9H), 4.61(d,1H,J=11.3Hz),
4.79(d,1H,J=11.3Hz), 5.4(d,1H,J=9.0Hz), 5.75(brd,1
H,J=9.0Hz), 6.00(br,1H), 6.52(br,1H), 7.35(s,5H) IR(NaCl) 1698(s), 1664(s), 1502(s), 732(m), 695
(m) cm-1 元素分析値 (C14H20O4N2):Cacld.C:59.99, H:7.19, N:
9.99 Obsd. C:59.94, H:7.33, N:10.28
The oily substance obtained was treated with ethanol (50 ml).
The resulting product was dissolved in water and excess ammonia was blown into the solution at 0 ° C., excess ammonia was removed under reduced pressure, the solvent was distilled off, and the resulting crude product was purified by silica gel column chromatography to obtain α-benzyloxy. -N-te
rt-Butoxycarbonylglycinamide (0.397
g, 22%). mp 115-120 ℃ 1 HNMR δ (CDCl 3 ) 1.44 (s, 9H), 4.61 (d, 1H, J = 11.3Hz),
4.79 (d, 1H, J = 11.3Hz), 5.4 (d, 1H, J = 9.0Hz), 5.75 (brd, 1
H, J = 9.0Hz), 6.00 (br, 1H), 6.52 (br, 1H), 7.35 (s, 5H) IR (NaCl) 1698 (s), 1664 (s), 1502 (s), 732 (m ), 695
(m) cm -1 Elemental analysis value (C 14 H 20 O 4 N 2 ): Cacld. C: 59.99, H: 7.19, N:
9.99 Obsd. C: 59.94, H: 7.33, N: 10.28

【0033】実施例3.前記1−2又は1−3に従って
製造したα−ヒドロキシ−N−tert−ブトキシカル
ボニルグリシンメチルエステル(2.07g,10.1
mmol)をDMF(20ml)に溶かし、室温で酸化銀
(1.39g,6.0mmol)及びヨウ化アリル(1.2
ml,12.9mmol)を加えた。そのまま室温で一昼夜攪
拌した後、沈澱をろ別し母液に水を加えて酢酸エチルで
抽出した。抽出溶液を無水硫酸マグネシウムで乾燥した
後、溶媒を留去して更にチオ硫酸ナトリウム水溶液を加
え、酢酸エチルにより抽出し反応副生成物であるヨウ素
を取り除いた。
Example 3. Α-Hydroxy-N-tert-butoxycarbonylglycine methyl ester prepared according to 1-2 or 1-3 above (2.07 g, 10.1
mmol) in DMF (20 ml), and at room temperature silver oxide (1.39 g, 6.0 mmol) and allyl iodide (1.2).
ml, 12.9 mmol) was added. The mixture was stirred at room temperature for 24 hours, the precipitate was filtered off, water was added to the mother liquor, and the mixture was extracted with ethyl acetate. The extracted solution was dried over anhydrous magnesium sulfate, the solvent was distilled off, an aqueous sodium thiosulfate solution was added, and the mixture was extracted with ethyl acetate to remove iodine as a by-product of the reaction.

【0034】得られた油状物質をエタノール(50ml)
に溶かしその溶液に0℃で過剰のアンモニアを吹き込ん
だ後、余剰のアンモニアを減圧下で取り除き、溶媒を留
去し得られた粗生成物をシリカゲルカラムクロマトグラ
フィーにより精製し、α−アリルオキシ−N−tert
−ブトキシカルボニルグリシンアミド(0.625g,
27%)を得た。1 HNMR δ(CDCl3) 1.45(s,9H), 4.14(dd,2H,J=7.2,1.8H
z), 5.11-5.56(m,3H), 5.70-6.20(m,2H), 6.33-7.01(m,
2H) IR(CDCl3) 2975(w), 1705(s, br), 1498(m), 990(sh.
w) cm -1
The oily substance obtained was treated with ethanol (50 ml).
And blowing excess ammonia at 0 ° C. into the solution, the excess ammonia was removed under reduced pressure, the solvent was distilled off and the resulting crude product was purified by silica gel column chromatography to obtain α-allyloxy-N. -Tert
-Butoxycarbonylglycinamide (0.625 g,
27%). 1 HNMR δ (CDCl 3 ) 1.45 (s, 9H), 4.14 (dd, 2H, J = 7.2,1.8H
z), 5.11-5.56 (m, 3H), 5.70-6.20 (m, 2H), 6.33-7.01 (m,
2H) IR (CDCl 3 ) 2975 (w), 1705 (s, br), 1498 (m), 990 (sh.
w) cm -1

【0035】実施例4. 4−1 α−ヒドロキシ−N−ベンジルオキシカルボニルグリシ
ン(4.44g,19.7mmol)をメタノール(20m
l)に溶かした溶液に、0℃で塩化チオニル(2.9m
l,40.0mmol)を滴下してその温度で30分攪拌
し、さらに室温で2時間攪拌した。その後溶媒を留去し
得られた粗生成物をメタノール(50ml)に溶かした溶
液を0℃に冷却し、過剰のアンモニアを吹き込んだ。
Example 4. 4-1 α-hydroxy-N-benzyloxycarbonylglycine (4.44 g, 19.7 mmol) was added to methanol (20 m
l) in a solution of thionyl chloride (2.9 m
(1, 40.0 mmol) was added dropwise, and the mixture was stirred at that temperature for 30 minutes and further at room temperature for 2 hours. Then, the solvent was distilled off, and the resulting crude product was dissolved in methanol (50 ml). The solution was cooled to 0 ° C., and excess ammonia was blown thereinto.

【0036】反応終了後、余剰のアンニモアを減圧下で
除去し溶媒を留去して得た白色結晶を、シリカゲルカラ
ムクロマトグラフィーにより精製して、α−メトキシ−
N−ベンジルオキシカルボニルグリシンアミド(3.4
2g,73%)を得た。 m.p. 110−112 ℃1 HNMR δ(CDCl3) 3.44(s,3H), 5.16(s,2H), 5.31(d,1H,
J=8.8Hz), 5.45-5.98(br,2H), 6.28-6.68(br,1H), 7.36
(s,5H) IR(NaCl) 1680(s. br), 1540(s), 1520(s), 860(m), 7
00(m) cm-1 元素分析値 (C11H14O4N2):Calcd.C:55.46, H:5.92, N:1
1.76 Obsd. C:55.70, H:5.94, N:11.58
After the completion of the reaction, excess annimore was removed under reduced pressure and the solvent was distilled off to obtain white crystals, which were purified by silica gel column chromatography to obtain α-methoxy-
N-benzyloxycarbonylglycinamide (3.4
2 g, 73%) was obtained. mp 110-112 ℃ 1 HNMR δ (CDCl 3 ) 3.44 (s, 3H), 5.16 (s, 2H), 5.31 (d, 1H,
J = 8.8Hz), 5.45-5.98 (br, 2H), 6.28-6.68 (br, 1H), 7.36
(s, 5H) IR (NaCl) 1680 (s.br), 1540 (s), 1520 (s), 860 (m), 7
00 (m) cm -1 Elemental analysis value (C 11 H 14 O 4 N 2 ): Calcd.C: 55.46, H: 5.92, N: 1
1.76 Obsd. C: 55.70, H: 5.94, N: 11.58

【0037】4−2 前記1−4における出発物質α−ヒドロキシ−N−ベン
ジルオキシカルボニルグリシンは次のようにして製造し
た。カルバミン酸ベンジル(30.24g,0.2mol)
とグリオキシル酸一水和物(20.26g,0.22mo
l)をジエチルエーテル(200ml)に溶かし、室温で一
昼夜攪拌した後、生成した結晶をろ過、続くエーテル洗
浄によって純粋なα−ヒドロキシ−N−ベンジルオキシ
カルボニルグリシン(33.78g,75%)を得た。 m.p. 200−205 ℃(分解)1 HNMR δ(CD3OD) 5.12(s,2H), 5.40(s,1H), 7.34(s,5H)
4-2 The starting material α-hydroxy-N-benzyloxycarbonylglycine in 1-4 above was prepared as follows. Benzyl carbamate (30.24g, 0.2mol)
And glyoxylic acid monohydrate (20.26g, 0.22mo
l) was dissolved in diethyl ether (200 ml) and the mixture was stirred at room temperature for 24 hours, and the resulting crystals were filtered and washed with ether to give pure α-hydroxy-N-benzyloxycarbonylglycine (33.78 g, 75%). It was mp 200-205 ℃ (decomposition) 1 HNMR δ (CD 3 OD) 5.12 (s, 2H), 5.40 (s, 1H), 7.34 (s, 5H)

【0038】実施例5.前記4−2に従って製造したα
−ヒドロキシ−N−ベンジルオキシカルボニルグリンシ
(2.26g,10.0mmol)をエタノール(20ml)
に溶かした溶液に、−10℃で塩化チオニル(2ml,2
7.4mmol) を滴下し、室温で一昼夜攪拌した。その後
溶媒を留去して得られた粗生成物をシリカゲルカラムク
ロマトグラフィーにより精製して、α−エトキシ−N−
ベンジルオキシカルボニルグリシンエチルエステル
(2.81g,quant.)を得た。 m.p. 66 −68℃1 HNMR δ(CDCl3) 1.22(t,3H,J=7.2Hz), 1.30(t,3H,J=7.
2Hz), 3.70(q,2H,J=7.2Hz), 4.24(q,2H,J=7.2Hz), 5.15
(s,2H), 5.33(d,1H,J=9.7Hz), 5.93(brd,1H,J=9.7Hz),
7.35(s,5H) IR(NaCl) 1740(s), 1700(s), 1540(s), 760(m), 700
(m) cm-1 元素分析値 (C14H19O5N): Calcd. C:59.78, H:6.81, N:
4.98 Obsd. C:60.03, H:6.88, N:4.89
Example 5. Α produced according to 4-2 above
-Hydroxy-N-benzyloxycarbonyl grind (2.26 g, 10.0 mmol) in ethanol (20 ml)
Thionyl chloride (2 ml, 2 ml) at -10 ° C.
(7.4 mmol) was added dropwise, and the mixture was stirred at room temperature for 24 hours. After that, the solvent was distilled off and the obtained crude product was purified by silica gel column chromatography to obtain α-ethoxy-N-
Benzyloxycarbonylglycine ethyl ester (2.81 g, quant.) Was obtained. mp 66 −68 ℃ 1 HNMR δ (CDCl 3 ) 1.22 (t, 3H, J = 7.2Hz), 1.30 (t, 3H, J = 7.
2Hz), 3.70 (q, 2H, J = 7.2Hz), 4.24 (q, 2H, J = 7.2Hz), 5.15
(s, 2H), 5.33 (d, 1H, J = 9.7Hz), 5.93 (brd, 1H, J = 9.7Hz),
7.35 (s, 5H) IR (NaCl) 1740 (s), 1700 (s), 1540 (s), 760 (m), 700
(m) cm -1 Elemental analysis value (C 14 H 19 O 5 N): Calcd. C: 59.78, H: 6.81, N:
4.98 Obsd. C: 60.03, H: 6.88, N: 4.89

【0039】実施例6.前記4−2に従って製造したα
−ヒドロキシ−N−ベンジルオキシカルボニルグリシン
(2.26g,10.0mmol)をイソプロピルアルコー
ル(20ml)に溶かした溶液に、−10℃で塩化チオニ
ル(2ml,27.4mmol)を滴下し、室温で一昼夜攪拌
した。その後溶媒を留去して得られた粗生成物をシリカ
ゲルカラムクロマトグラフィーにより精製して、α−イ
ソプロポキシ−N−ベンジルオキシカルボニルグリシン
イソプロピルエステル(3.10g,quant.)を
得た。1 HNMR δ(CDCl3) 1.16-1.37(m,12H), 3.87-4.22(m,1H),
4.57-5.20(m,1H), 5.14(s,2H), 5.33(d,1H,J=9.7Hz),
5.93(brd,1H,J=9.7Hz), 7.35(s,5H) IR(Neat) 1728(s,br), 1508(m), 740(m) cm-1
Example 6. Α produced according to 4-2 above
To a solution of -hydroxy-N-benzyloxycarbonylglycine (2.26 g, 10.0 mmol) in isopropyl alcohol (20 ml) was added thionyl chloride (2 ml, 27.4 mmol) dropwise at -10 ° C, and the mixture was allowed to stand at room temperature overnight. It was stirred. Then, the solvent was distilled off and the obtained crude product was purified by silica gel column chromatography to obtain α-isopropoxy-N-benzyloxycarbonylglycine isopropyl ester (3.10 g, quant.). 1 HNMR δ (CDCl 3 ) 1.16-1.37 (m, 12H), 3.87-4.22 (m, 1H),
4.57-5.20 (m, 1H), 5.14 (s, 2H), 5.33 (d, 1H, J = 9.7Hz),
5.93 (brd, 1H, J = 9.7Hz), 7.35 (s, 5H) IR (Neat) 1728 (s, br), 1508 (m), 740 (m) cm -1

【0040】実施例7.実施例5に従って製造したα−
エトキシ−N−ベンジルオキシカルボニルグリシンエチ
ルエステル(2.29g,8.1mmol)をエタノール
(80ml)に溶かし、0℃に冷却してその温度で過剰の
アンモニアを吹き込んだ。反応終了後、余剰のアンモニ
アを減圧下で除去し溶媒を留去して得た白色結晶をヘキ
サン−酢酸エチル混合溶液で洗浄し、純粋なα−エトキ
シ−N−ベンジルオキシカルボニルグリシンアミド
(1.51g,77%)を得た。 m.p. 119−121 ℃1 HNMR δ(CDCl3) 1.23(t,3H,J=7.1Hz), 3.50-3.90(m,2
H), 5.14(s,2H), 5.37(d,1H,J=9.0Hz), 5.65-5.96(br,2
H), 6.41-6.71(br,1H), 7.35(s,5H) IR(NaCl) 1680(s), 1664(s), 1542(m), 1524(m), 760
(w), 740(w), 700(m) cm -1 元素分析値 (C12H16O4N2): Calcd. C:57.13, H:6.39,
N:11.10 Obsd. C:57.09, H:6.34, N:11.37
[0040]Example 7.Α-prepared according to Example 5
Ethoxy-N-benzyloxycarbonylglycine ethyl
Ruester (2.29 g, 8.1 mmol) in ethanol
Dissolve in (80 ml), cool to 0 ° C. and add excess
Bubbling ammonia. After the reaction is completed, the excess ammoni
Was removed under reduced pressure and the solvent was distilled off to give white crystals.
Wash with a mixed solution of sun-ethyl acetate to obtain pure α-ethoxide.
Ci-N-benzyloxycarbonylglycinamide
(1.51 g, 77%) was obtained. m.p. 119-121 ° C1 HNMR δ (CDCl3) 1.23 (t, 3H, J = 7.1Hz), 3.50-3.90 (m, 2
H), 5.14 (s, 2H), 5.37 (d, 1H, J = 9.0Hz), 5.65-5.96 (br, 2
H), 6.41-6.71 (br, 1H), 7.35 (s, 5H) IR (NaCl) 1680 (s), 1664 (s), 1542 (m), 1524 (m), 760
(w), 740 (w), 700 (m) cm -1 Elemental analysis value (C12H16OFourN2): Calcd. C: 57.13, H: 6.39,
N: 11.10 Obsd. C: 57.09, H: 6.34, N: 11.37

【0041】実施例8.実施例6に従って製造したα−
イソプロポキシ−N−ベンジルオキシカルボニルグリシ
ンイソプロピルエステル(2.48g,8.0mmol)を
エタノール(40ml)に溶かし、0℃に冷却してその温
度で過剰のアンモニアを5時間吹き込みさらにアンモニ
ア飽和状態で二日間攪拌した。反応終了後、余剰のアン
モニアを減圧下で除去し溶媒を留去して得た白色結晶を
ヘキサン−酢酸エチル混合溶液で洗浄し、純粋なα−イ
ソプロポキシ−N−ベンジルオキシカルボニルグリシン
アミド(1.64g,77%)を得た。 m.p. 111−113 ℃1 HNMR δ(CDCl3) 1.18(d,3H,J=4.4Hz), 1.25(d,3H,J=4.
4Hz), 3.81-4.20(m,1H),5.15(s,2H), 5.44(d,1H,J=9.0H
z), 5.53-5.86(br,2H), 6.37-6.73(br,1H), 7.35(s,5H) IR(NaCl) 1668(s), 1660(s), 1538(m), 1530(m), 760
(w), 740(w), 700(m) cm -1 元素分析値 (C13H18O4N2): Calcd. C:58.63, H:6.81,
N:10.52 Obsd. C:58.60, H:6.82, N:10.54
[0041]Example 8.Α-prepared according to Example 6
Isopropoxy-N-benzyloxycarbonylglycy
Isopropyl ester (2.48 g, 8.0 mmol)
Dissolve in ethanol (40 ml), cool to 0 ° C and warm
Blow excess ammonia for 5 hours depending on the temperature
The mixture was stirred for 2 days in a saturated state. After the reaction is complete,
The white crystals obtained by removing the monia under reduced pressure and distilling off the solvent
It was washed with a mixed solution of hexane-ethyl acetate to obtain pure α-ethyl acetate.
Sopropoxy-N-benzyloxycarbonylglycine
The amide (1.64 g, 77%) was obtained. m.p. 111-113 ℃1 HNMR δ (CDCl3) 1.18 (d, 3H, J = 4.4Hz), 1.25 (d, 3H, J = 4.
4Hz), 3.81-4.20 (m, 1H), 5.15 (s, 2H), 5.44 (d, 1H, J = 9.0H
z), 5.53-5.86 (br, 2H), 6.37-6.73 (br, 1H), 7.35 (s, 5H) IR (NaCl) 1668 (s), 1660 (s), 1538 (m), 1530 (m) , 760
(w), 740 (w), 700 (m) cm -1 Elemental analysis value (C13H18OFourN2): Calcd. C: 58.63, H: 6.81,
N: 10.52 Obsd. C: 58.60, H: 6.82, N: 10.54

【0042】実施例9.実施例1(1−1)に従って製
造したα−tert−ブチルジメチルシリルオキシ−N
−tert−ブトキシカルボニルグリシンアミド(5.
08g,16.7mmol)をジオキサン(10ml)に溶か
し、0℃に冷却して4N塩酸/ジオキサン溶液(17m
l)を加え、その温度で1時間攪拌した。反応を完結さ
せるために更にその温度で4N−塩酸/ジオキサン溶液
を加え、室温まで温度を上げて1時間攪拌した。その後
溶液にジエチルエーテルを加え、生成物をできるだけ沈
澱させてろ過し、更にエーテルで洗浄した後、沈澱を減
圧下で乾燥し純粋なα−ヒドロキシグリシンアミド塩酸
塩(1.86g,88%)を得た。1 HNMR δ(DMSO-d6) 4.99(br s,1H), 7.62-8.03(br,2H),
8.32-8.85(br,3H) IR(KBr) 1686(s), 1581(m), 1546(m),1477(s), 843(m)
cm-1
Example 9. Α-tert-butyldimethylsilyloxy-N produced according to Example 1 (1-1)
-Tert-butoxycarbonylglycinamide (5.
08g, 16.7mmol) was dissolved in dioxane (10ml), cooled to 0 ° C and 4N hydrochloric acid / dioxane solution (17m).
l) was added and stirred at that temperature for 1 hour. In order to complete the reaction, 4N-hydrochloric acid / dioxane solution was further added at that temperature, the temperature was raised to room temperature, and the mixture was stirred for 1 hour. After that, diethyl ether was added to the solution, and the product was precipitated as much as possible, filtered, washed with ether, and dried under reduced pressure to obtain pure α-hydroxyglycinamide hydrochloride (1.86 g, 88%). Obtained. 1 HNMR δ (DMSO-d 6 ) 4.99 (br s, 1H), 7.62-8.03 (br, 2H),
8.32-8.85 (br, 3H) IR (KBr) 1686 (s), 1581 (m), 1546 (m), 1477 (s), 843 (m)
cm -1

【0043】実施例10.実施例4(4−1)に従って
製造したα−メトキシ−N−ベンジルオキシカルボニル
グリシンアミド(0.24g,1.0mmol)をメタノー
ルに溶かし、室温で12Nの塩酸(0.1ml)及びパラ
ジウム−炭素(50mg)を加え水素雰囲気下で、30分
攪拌した。その後パラジウム−炭素をろ別し、母液の溶
媒を留去することにより目的とするα−メトキシグリシ
ンアミド塩酸塩(0.14g,quant)を得た。1 HNMR δ(CD3OD) 3.35(s,3H), 5.01(s,1H)13 CNMRδ(CD3OD) 42.1, 84.3(d,J=159.8Hz), 170.3
Example 10. Α-Methoxy-N-benzyloxycarbonylglycinamide (0.24 g, 1.0 mmol) prepared according to Example 4 (4-1) was dissolved in methanol, and 12N hydrochloric acid (0.1 ml) and palladium-carbon were added at room temperature. (50 mg) was added, and the mixture was stirred under a hydrogen atmosphere for 30 minutes. Then, palladium-carbon was filtered off, and the solvent of the mother liquor was distilled off to obtain the desired α-methoxyglycinamide hydrochloride (0.14 g, quant). 1 HNMR δ (CD 3 OD) 3.35 (s, 3H), 5.01 (s, 1H) 13 CNMR δ (CD 3 OD) 42.1, 84.3 (d, J = 159.8Hz), 170.3

【0044】実施例11. アミノ酸のアミド化 実施例9に従って製造したα−ヒドロキシグリシンアミ
ド塩酸塩(72.6mg,0.57mmol)、N−tert
−ブトキシカルボニル−フェニルアラニン(125.8
mg,0.48mmol)、及びN−ヒドロキシベンゾトリア
ゾール(78mg,0.58mmol)をジメチルホルムアミ
ド(4ml)に溶かし、−10℃に冷却して水溶性カルボ
ジイミド(0.1ml,0.55mmol)を滴下し0℃まで
温度を上げて2時間攪拌した。
Example 11. Amino acid amidation α-Hydroxyglycinamide hydrochloride prepared according to Example 9 (72.6 mg, 0.57 mmol), N-tert.
-Butoxycarbonyl-phenylalanine (125.8
mg, 0.48 mmol) and N-hydroxybenzotriazole (78 mg, 0.58 mmol) were dissolved in dimethylformamide (4 ml), cooled to -10 ° C and water-soluble carbodiimide (0.1 ml, 0.55 mmol) was added dropwise. Then, the temperature was raised to 0 ° C. and the mixture was stirred for 2 hours.

【0045】その後水を加えてクロロホルムで抽出し有
機層を無水硫酸マグネシウムで乾燥し溶媒を留去、得ら
れた粗生成物を分取用TLCを用いて精製し、目的とす
るN−tert−ブトキシカルボニル−フェニルアラニ
ンアミド(38mg,30%)を得た。 m.p. 142−149 ℃ 〔α〕D =+16.5°(EtOH , c=1.17)1 HNMR δ(CDC13) 1.40(s,2H), 3.07(d,2H,J=6.8Hz), 4.
36(dt,1H,J=7.9,6.9), 4.92-5.20(brd,1H), 5.32-5.59
(br,1H), 5.59-5.93(br,1H), 7.25(s,5H)
Thereafter, water was added and the mixture was extracted with chloroform, the organic layer was dried over anhydrous magnesium sulfate, the solvent was distilled off, and the obtained crude product was purified by preparative TLC to obtain the desired N-tert- Butoxycarbonyl-phenylalanine amide (38 mg, 30%) was obtained. mp 142-149 ° C (α) D = + 16.5 ° (EtOH, c = 1.17) 1 HNMR δ (CDC1 3 ) 1.40 (s, 2H), 3.07 (d, 2H, J = 6.8Hz), 4.
36 (dt, 1H, J = 7.9,6.9), 4.92-5.20 (brd, 1H), 5.32-5.59
(br, 1H), 5.59-5.93 (br, 1H), 7.25 (s, 5H)

【0046】実施例12. アミノ酸のアミド化 実施例9に従って製造したα−ヒドロキシグリシンアミ
ド塩酸塩(0.122g,9.6mmol)、N−tert
−ブトキシカルボニル−プロリン(0.169g,0.
79mmol)、及びN−ヒドロキシベンゾトリアゾール
(0.129g,0.95mmol)をジメチルホルムアミ
ド(5ml)に溶かし、−10℃に冷却して水溶性カルボ
ジイミド(0.1ml,0.55mmol)を滴下した。その
温度で5分間攪拌した後、0℃まで温度を上げてさらに
4時間攪拌した。
Example 12 Amino acid amidation α-hydroxyglycinamide hydrochloride prepared according to Example 9 (0.122 g, 9.6 mmol), N-tert.
-Butoxycarbonyl-proline (0.169 g, 0.
79 mmol) and N-hydroxybenzotriazole (0.129 g, 0.95 mmol) were dissolved in dimethylformamide (5 ml), cooled to -10 ° C and water-soluble carbodiimide (0.1 ml, 0.55 mmol) was added dropwise. After stirring at that temperature for 5 minutes, the temperature was raised to 0 ° C. and stirring was continued for 4 hours.

【0047】その後食塩水を加えてクロロホルムで抽出
し有機層を無水硫酸マグネシウムで乾燥し溶媒を留去、
得られた粗生成物をシリカゲルカラムクロマトグラフィ
ーにより精製し、目的とするN−tert−ブトキシカ
ルボニル−プロリンアミド(0.081g,48%)を
得た。 m.p. 104−106 ℃ 〔α〕D =−40.5°(EtOH , C=1.1)1 HNMR δ(CDC13) 1.40(s,9H), 1.65-2.48(m,4H), 3.27-
3.63(brt,2H), 4.18-4.41(br,1H), 5.88-7.02(br,2H)
After that, saline was added and the mixture was extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate and the solvent was distilled off.
The obtained crude product was purified by silica gel column chromatography to obtain the desired N-tert-butoxycarbonyl-prolinamide (0.081 g, 48%). mp 104-106 ℃ (α) D = -40.5 ° (EtOH, C = 1.1) 1 HNMR δ (CDC1 3 ) 1.40 (s, 9H), 1.65-2.48 (m, 4H), 3.27-
3.63 (brt, 2H), 4.18-4.41 (br, 1H), 5.88-7.02 (br, 2H)

【0048】実施例13. トリペプチドのアミド化 実施例9に従って製造したα−ヒドロキシグリシンアミ
ド塩酸塩(0.58g,4.6mmol)、N−tert−
ブトキシカルボニル−L−プロリル−L−ロイシル−グ
リシン(1.37g,4.2mmol)、及びN−ヒドロキ
シベンゾトリアゾール(0.63g,4.7mmol)をジ
メチルホルムアミド(15ml)に溶かし、−10℃に冷
却して水溶性カルボジイミド(0.85ml,4.6mmo
l)を滴下した。その温度で20分間攪拌した後、0℃
まで温度を上げてさらに一昼夜攪拌した。
Example 13. Amidation of tripeptides α-Hydroxyglycinamide hydrochloride prepared according to Example 9 (0.58 g, 4.6 mmol), N-tert-
Butoxycarbonyl-L-prolyl-L-leucyl-glycine (1.37 g, 4.2 mmol) and N-hydroxybenzotriazole (0.63 g, 4.7 mmol) were dissolved in dimethylformamide (15 ml), and the mixture was heated to -10 ° C. Cool to water-soluble carbodiimide (0.85 ml, 4.6 mmo)
l) was added dropwise. After stirring for 20 minutes at that temperature, 0 ° C
The temperature was raised to and the mixture was further stirred overnight.

【0049】その後食塩水を加えてクロロホルムで抽出
し有機層を無水硫酸マグネシウムで乾燥し溶媒を留去、
得られた粗生成物をシリカゲルカラムクロマトグラフィ
ーにより精製し、目的とするN−tert−ブトキシカ
ルボニル−L−プロリル−L−ロイシル−グリシンアミ
ド(0.726g,53%)を得た。 m.p. 119−121 ℃ 〔α〕D =−51.0°(DMF, C=0.73)1 HNMR δ(CDC13) 0.91(d,3H,J=5.4Hz), 0.95(d,3H,J=5.
4Hz),1.46(s,9H), 1.20-2.45(m.7H), 3.45(t,2H,J=6.6H
z), 3.91(brd,2H,J=5.93Hz), 4.08-4.53(m.2H),5.78(b
s,1H), 6.76(bs,1H), 7.03(bs,1H)
Thereafter, saline was added thereto, extraction was performed with chloroform, the organic layer was dried over anhydrous magnesium sulfate, and the solvent was distilled off.
The obtained crude product was purified by silica gel column chromatography to obtain the desired N-tert-butoxycarbonyl-L-prolyl-L-leucyl-glycinamide (0.726 g, 53%). mp 119-121 ° C (α) D = -51.0 ° (DMF, C = 0.73) 1 HNMR δ (CDC1 3 ) 0.91 (d, 3H, J = 5.4Hz), 0.95 (d, 3H, J = 5.
4Hz), 1.46 (s, 9H), 1.20-2.45 (m.7H), 3.45 (t, 2H, J = 6.6H
z), 3.91 (brd, 2H, J = 5.93Hz), 4.08-4.53 (m.2H), 5.78 (b
s, 1H), 6.76 (bs, 1H), 7.03 (bs, 1H)

【0050】実施例14. アミノ酸のアミド化 実施例10に従ってα−メトキシグリシンアミド塩酸塩
(70mg,0.5mmol) 、N−tert−ブトキシカル
ボニル−フェニルアラニン(106mg,0.4mmol)、
及びN−ヒドロキシベンゾトリアゾール(69mg,0.
5mmol)をジメチルホルムアミド(2ml)に溶かし、−
10℃に冷却して水溶性カルボジイミド(0.1ml,
0.55mmol)を滴下し、0℃まで温度を上げて2.5
時間攪拌した。その後食塩水を加えてクロロホルムで抽
出し有機層を無水硫酸マグネシウムで乾燥し溶媒を留
去、得られた粗生成物をシリカゲルカラムクロマトグラ
フィーにより精製し、目的とするN−tert−ブトキ
シカルボニル−フェニルアラニンアミド(37mg,35
%)を得た。
Example 14 Amino acid amidation α-methoxyglycinamide hydrochloride (70 mg, 0.5 mmol), N-tert-butoxycarbonyl-phenylalanine (106 mg, 0.4 mmol), according to Example 10.
And N-hydroxybenzotriazole (69 mg, 0.
5 mmol) in dimethylformamide (2 ml),
Water-soluble carbodiimide (0.1 ml,
0.55 mmol) was added dropwise and the temperature was raised to 0 ° C. to reach 2.5
Stir for hours. After that, brine was added thereto, the mixture was extracted with chloroform, the organic layer was dried over anhydrous magnesium sulfate, the solvent was distilled off, and the obtained crude product was purified by silica gel column chromatography to obtain the desired N-tert-butoxycarbonyl-phenylalanine. Amide (37 mg, 35
%) Was obtained.

【0051】実施例15.α−ヒドロキシ−N−ter
t−ブトキシカルボニルグリシンメチルエステル(1.
03g,5.0mmol) 及びイミダゾール(0.41g,
6.1mmol) をジメチルホルムアミド(3ml) に溶解
し、そしてこの溶液を−10℃に冷却した。この溶液に
tert−ブチルジフェニルシリルクロリド(TBDP
SCl)を添加し、そして混合物を室温にて2時間攪拌
した。この混合物を水で希釈し、そして酢酸エチルで溶
出した。有機相を塩水で洗浄し、そして無水硫酸マグネ
シウムで乾燥し、そして溶剤を減圧下で蒸発させた。
Example 15 α-hydroxy-N-ter
t-Butoxycarbonylglycine methyl ester (1.
03 g, 5.0 mmol) and imidazole (0.41 g,
6.1 mmol) was dissolved in dimethylformamide (3 ml) and the solution was cooled to -10 ° C. Tert-Butyldiphenylsilyl chloride (TBDP
SCl) was added and the mixture was stirred at room temperature for 2 hours. The mixture was diluted with water and eluted with ethyl acetate. The organic phase was washed with brine and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure.

【0052】生成する結晶性残渣をエタノール(100
ml)に溶解し、そしてこの溶液に0℃にて3時間アンモ
ニアを吹き込んだ。5℃にてさらに1時間攪拌した後、
過剰のアンモニアを真空蒸発せしめた。溶剤の蒸発の
後、粗生成物をシリカゲルカラムクロマトグラフィー
(ヘキサン/酢酸エチル)により精製してα−tert
−ブチルジフェニルシリルオキシ−N−tert−ブト
キシカルボニルグリシンアミド(2.14g、定量的)
を得た。1 HNMR δ(CDC13) 1.07(s,9H), 1.31(s,9H), 5.25(d,1H,
J=8.7Hz), 5.44(d,1H,J=8.7Hz), 6.14(br,1H), 6.49(b
s,1H), 7.26-7.55(m.6H), 7.58-7.82(m,4H) IR(NaCl) 1708(s), 1690(s), 1678(s), 1520(m), 1080
(br,m), 740(m), 700(m)cm -1
The resulting crystalline residue was treated with ethanol (100
ml), and the solution was bubbled with ammonia at 0 ° C. for 3 hours. After stirring at 5 ° C for another hour,
Excess ammonia was evaporated in vacuo. After evaporation of the solvent, the crude product was purified by silica gel column chromatography (hexane / ethyl acetate) to obtain α-tert.
-Butyldiphenylsilyloxy-N-tert-butoxycarbonylglycinamide (2.14 g, quantitative)
Got 1 HNMR δ (CDC1 3 ) 1.07 (s, 9H), 1.31 (s, 9H), 5.25 (d, 1H,
J = 8.7Hz), 5.44 (d, 1H, J = 8.7Hz), 6.14 (br, 1H), 6.49 (b
s, 1H), 7.26-7.55 (m.6H), 7.58-7.82 (m, 4H) IR (NaCl) 1708 (s), 1690 (s), 1678 (s), 1520 (m), 1080
(br, m), 740 (m), 700 (m) cm -1

【0053】実施例16.α−ヒドロキシ−N−ベンジ
ルオキシカルボニルグリシン(1.12g,5.0mmo
l) を2−プロピン−1−オール(5ml)に溶解し、そ
して0℃にて塩化チオニル(1.1ml,15mmol)を滴
加した。混合物を0℃から室温になるまで14時間攪拌
した。溶剤を真空除去し、そして生ずる粗生成物をエタ
ノール(30ml)に溶解した。この溶液に0℃にてアン
モニアを吹き込み、そしてこの混合物をアンモニア雰囲
気下、室温にて一夜攪拌した。
Example 16. α-Hydroxy-N-benzyloxycarbonylglycine (1.12g, 5.0mmo
l) was dissolved in 2-propyn-1-ol (5 ml) and thionyl chloride (1.1 ml, 15 mmol) was added dropwise at 0 ° C. The mixture was stirred from 0 ° C. to room temperature for 14 hours. The solvent was removed in vacuo and the resulting crude product was dissolved in ethanol (30 ml). Ammonia was bubbled through the solution at 0 ° C., and the mixture was stirred at room temperature under ammonia atmosphere overnight.

【0054】過剰のアンモニアを真空除去し、そして溶
剤を減圧蒸発せしめた。生成する油状残渣をシリカゲル
カラムクロマトグラフィー(酢酸エチル)により精製し
てa−(2−プロピン−1−オキシ)−N−ベンジルオ
キシカルボニルグリシンアミド(1.22g,93%)
を得た。 m.p. 80 −83℃1 HNMR δ(CDC13) 2.46(t,1H,J=2.4Hz), 4.28(d,2H,J=2.
4Hz), 5.10(s,2H),5.48(d,1H,J=8.8Hz), 6.48(d,1H,J=
8.8Hz), 6.65(bs,2H), 7.31(S,5H). IR(NaCl) 2125(w), 1704(s), 1680(s), 1522(s), 758
(w), 740(m), 700(m) cm -1 元素分析値 (C13H14N2O4):計算値 C:59.54, H:5.38, N:
10.68 測定値 C:59.73, H:5.51, N:10.33
Excess ammonia was removed by vacuum and dissolved.
The agent was evaporated under reduced pressure. The resulting oily residue is silica gel
Purified by column chromatography (ethyl acetate)
A- (2-propyne-1-oxy) -N-benzylo
Xycarbonyl glycinamide (1.22g, 93%)
Got m.p. 80 −83 ℃1 HNMR δ (CDC13) 2.46 (t, 1H, J = 2.4Hz), 4.28 (d, 2H, J = 2.
4Hz), 5.10 (s, 2H), 5.48 (d, 1H, J = 8.8Hz), 6.48 (d, 1H, J =
8.8Hz), 6.65 (bs, 2H), 7.31 (S, 5H) .IR (NaCl) 2125 (w), 1704 (s), 1680 (s), 1522 (s), 758
(w), 740 (m), 700 (m) cm -1 Elemental analysis value (C13H14N2OFour): Calculated value C: 59.54, H: 5.38, N:
10.68 Measured value C: 59.73, H: 5.51, N: 10.33

【0055】実施例17.N−tert−ブトキシカル
ボニル−L−プロリル−L−ロイシル−グリシンアミド
(0.325g,1.0mmol) をジオキサン(2ml)に
溶解し、そして0℃に冷却した。この溶液にジオキサン
(3ml)中4N塩酸をこの温度において添加し、そして
混合物を室温にて2.5時間攪拌した。
Example 17 N-tert-butoxycarbonyl-L-prolyl-L-leucyl-glycinamide (0.325 g, 1.0 mmol) was dissolved in dioxane (2 ml) and cooled to 0 ° C. To this solution was added 4N hydrochloric acid in dioxane (3 ml) at this temperature and the mixture was stirred at room temperature for 2.5 hours.

【0056】次に、この溶液にエーテルを加え、そして
生成する沈澱を澱過によりできるだけ多く集め、エーテ
ルで洗浄し、そして真空乾燥して純粋なL−プロリル−
L−ロイシル−L−グリシンアミドHCl塩(0.26
5g,96%)を得た。 〔α〕D =−40.9°(H2O, C=1.1)1 HNMR δ(D2O) 0.91(d,3H,J=5.8Hz), 0.95(d,3H,J=5.8
Hz), 1.66(m,3H), 2.08(m,3H), 2.46(m,1H), 3.43(m,tr
iplefoid,2H), 3.91(s.2H), 4.41(m.2H)
Ether is then added to this solution and the resulting precipitate is collected by filtration as much as possible, washed with ether and vacuum dried to give pure L-prolyl-.
L-leucyl-L-glycinamide HCl salt (0.26
5 g, 96%) was obtained. (Α) D = −4 0.9 ° (H 2 O, C = 1.1) 1 HNMR δ (D 2 O) 0.91 (d, 3H, J = 5.8Hz), 0.95 (d, 3H, J = 5.8)
Hz), 1.66 (m, 3H), 2.08 (m, 3H), 2.46 (m, 1H), 3.43 (m, tr
iplefoid, 2H), 3.91 (s.2H), 4.41 (m.2H)

【0057】実施例18.α−ヒドロキシグリシンアミ
ド塩酸塩(38mg, 0.3mmol) 、ピログルタミル−N
im−tert−ブトキシカルボニル−ヒスチジルプロリ
ン・トリエチルアミン塩(55mg、0.1mmol)及びN
−ヒドロキシベンゾトリアゾール(27mg,0.2mmo
l)をジメチルホルムアミド(0.5ml)に溶解し、そ
して−10℃に冷却した。この溶液に1−エチル−3−
(3−ジメチルアミノプロピル)カルボジイミド(36
μl,0.2mmol)を添加し、そしてこの混合物を同じ
温度にて2時間攪拌した。
Example 18 α-hydroxyglycinamide hydrochloride (38 mg, 0.3 mmol), pyroglutamyl-N
im -tert-butoxycarbonyl-histidylproline triethylamine salt (55 mg, 0.1 mmol) and N
-Hydroxybenzotriazole (27mg, 0.2mmo
l) was dissolved in dimethylformamide (0.5 ml) and cooled to -10 ° C. 1-Ethyl-3-
(3-Dimethylaminopropyl) carbodiimide (36
μl, 0.2 mmol) was added and the mixture was stirred at the same temperature for 2 hours.

【0058】室温にてさらに1時間攪拌した後、MPL
C装置を用いて混合物を直接カラムクロマトグラフィー
にかけた。粗生成物を分取用薄層クロマトグラフィー
(クロロホルム−メタノール)によりさらに精製してピ
ログルタミル−Nim−tert−ブトキシカルボニル−
ヒスチジルプロリンアミド(15mg,35%)を得た。 m.p. 155−160 ℃ 〔α〕D =−17.7°(MeOH, C=0.53)
After stirring at room temperature for another hour, MPL
The mixture was directly subjected to column chromatography using a C instrument. The crude product was purified by preparative thin layer chromatography - pyroglutamyl and further purification by crystallization (chloroform-methanol) -N im-tert-butoxycarbonyl -
Histidyl prolinamide (15 mg, 35%) was obtained. mp 155-160 ° C [α] D = -17.7 ° (MeOH, C = 0.53)

───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.5 識別記号 庁内整理番号 FI 技術表示箇所 C07K 7/36 8318−4H C07K 99:46 ─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. 5 Identification code Office reference number FI Technical display area C07K 7/36 8318-4H C07K 99:46

Claims (3)

【特許請求の範囲】[Claims] 【請求項1】 次の式(I): 【化1】 (式中、R1 は水素原子、低級アルキル基、低級アルケ
ニル基、低級アルキニル基、ベンジル基、又はアルキル
基によりもしくはアルキル基と芳香族基とにより置換さ
れたシリル基を表わし;R2 は水素原子又はアミノ保護
基を表わす)により表わされるα−ヒドロキシグリシン
アミド誘導体、及びその塩。
1. The following formula (I): (Wherein, R 1 represents a hydrogen atom, a lower alkyl group, lower alkenyl group, lower alkynyl group, a benzyl group, or an alkyl group with or an alkyl group and an aromatic group and a substituted silyl group; R 2 is hydrogen Α-hydroxyglycinamide derivative represented by the formula (1) representing an atom or an amino protecting group, and a salt thereof.
【請求項2】 請求項1に記載のα−ヒドロキシグリシ
ンアミド誘導体又はその塩の製造方法であって、次の式
(II): 【化2】 〔式中、R1 及びR2 は式(I)において定義したのと
同じ意味を有し、そしてR3 は水素原子又はカルボキシ
ル保護基である〕で表わされるα−ヒドロキシグリシン
誘導体を溶媒中アンモニアで処理し、所望によりアミノ
保護基を除去し、そして所望により得られた化合物をそ
の塩に転換することを特徴とする方法。
2. A method for producing an α-hydroxyglycinamide derivative or a salt thereof according to claim 1, which comprises the following formula (II): [Wherein R 1 and R 2 have the same meaning as defined in formula (I), and R 3 is a hydrogen atom or a carboxyl-protecting group]. And optionally removing the amino protecting group and optionally converting the resulting compound into its salt.
【請求項3】 アミノ酸もしくはペプチド又はこれらの
誘導体を請求項1に記載のα−ヒドロキシグリシン誘導
体と反応せしめることを特徴とするC−末端アミド化ペ
プチドの製造方法。
3. A method for producing a C-terminal amidated peptide, which comprises reacting an amino acid or a peptide or a derivative thereof with the α-hydroxyglycine derivative according to claim 1.
JP3256536A 1991-10-03 1991-10-03 Alpha-hydroxyglycinamide derivative and its production Pending JPH0597789A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP3256536A JPH0597789A (en) 1991-10-03 1991-10-03 Alpha-hydroxyglycinamide derivative and its production

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP3256536A JPH0597789A (en) 1991-10-03 1991-10-03 Alpha-hydroxyglycinamide derivative and its production

Publications (1)

Publication Number Publication Date
JPH0597789A true JPH0597789A (en) 1993-04-20

Family

ID=17293992

Family Applications (1)

Application Number Title Priority Date Filing Date
JP3256536A Pending JPH0597789A (en) 1991-10-03 1991-10-03 Alpha-hydroxyglycinamide derivative and its production

Country Status (1)

Country Link
JP (1) JPH0597789A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990278A (en) * 1994-09-02 1999-11-23 Hoffmann; Stefen Protective or anchor groups and their use
WO2004073703A1 (en) * 2003-02-21 2004-09-02 Tripep Ab Glycinamide derivative for inhibiting hiv replication
CN102351733A (en) * 2011-07-21 2012-02-15 凯莱英医药化学(阜新)技术有限公司 Method for preparing 2-amino-dimethyl acetamide hydrochloride

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990278A (en) * 1994-09-02 1999-11-23 Hoffmann; Stefen Protective or anchor groups and their use
WO2004073703A1 (en) * 2003-02-21 2004-09-02 Tripep Ab Glycinamide derivative for inhibiting hiv replication
CN102351733A (en) * 2011-07-21 2012-02-15 凯莱英医药化学(阜新)技术有限公司 Method for preparing 2-amino-dimethyl acetamide hydrochloride

Similar Documents

Publication Publication Date Title
KR910002544B1 (en) Nor-statine and nor-cylostatine polypeptides
JPH06340691A (en) Peptide
JPH0159278B2 (en)
DK149231B (en) METHOD OF ANALOGUE FOR THE PREPARATION OF ENKEPHALIN ANALOGUE TETRAPEPTIDAMIDES OR ACID ADDITION SALTS THEREOF
EP0368719B1 (en) Novel analogs of peptidase substrates
SK128694A3 (en) Cyclic amino acids, method of production of their d- and l-enanthiomers and semifinished products for their production
GB2127830A (en) Amides of tripeptides and tetrapeptides
JPH0597789A (en) Alpha-hydroxyglycinamide derivative and its production
JPH0647599B2 (en) Heptanoyl-Glu-Asp-Ala-amino acid immunostimulant
JP3165698B2 (en) Thioacylating reagents and intermediates, thiopeptides, and their preparation and use
JPH05117169A (en) Method for producing chloromethyl ketone
JPH08301831A (en) Stilbene derivative and carcinostatic agent containing the same
US6180759B1 (en) Process for the preparation of azacycloalkylakanoyl pseudotetrapeptides
Olsen et al. Synthesis of a model analog of the cyclic decadepsipeptide intercalating agent luzopeptin A (antibiotic BBM 928A) containing proline, valine, and unsubstituted quinoline substituents
JPH0753488A (en) Docosahexarnoic acid derivative
PT758342E (en) NEW PEPTID ACTIVE SUBSTANCE AND PREPARATION
US3749706A (en) Novel dipeptide amide and process for its manufacture
EP0406931B1 (en) New analogues of all-bond retroinverted thymopentin, the method for the synthesis of the same and their employment for the preparation of pharmaceutical compositions
US20070037845A1 (en) Peptido-mimetic compounds containing rgd sequence useful as integrin inhibitors, and intermediates thereof
JPS62132846A (en) 4-aminobutanoic acid derivative and manufacture
JPWO2015033781A1 (en) Method for producing dipeptide derivatives containing disubstituted amino acid residues
JP4050238B2 (en) Improved synthesis of KPV tripeptide diamide derivatives
JPH0254360B2 (en)
US3585180A (en) Process for preparing peptides containing histidine protected with a 2,2,2,-trihalogeno - n -benzyloxycarbonylaminoethyl group
JPH0339077B2 (en)